;

Egypt Immuno-Oncology Research Review Issue 5

In this issue:

  -  Polatuzumab vedotin in previously untreated DLBCL
  -  Second-line CAR T-cells in B-cell lymphoma
  -  Predicting CAR T-cell-related haematological toxicity in relapsed/refractory large B-cell lymphoma
  -  5-year results from ECHELON-2: brentuximab vedotin + CHP for CD30+ PTCL
  -  Pembrolizumab + rituximab in relapsed/refractory follicular lymphoma
  -  Tisagenlecleucel in relapsed/refractory extramedullary ALL
  -  Axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma
  -  SCT after CD19-CAR T-cellinduced ALL remission improves LFS
  -  Ciltacabtagene autoleucel vs. physician’s choice in relapsed/refractory MM

Download PDF Subscribe